THE RESEARCH THAT LEADS TO MYODM
According to the data obtained by Myogem Health Company from in vitro and in vivo experiments conducted over the past ten years, the product MYODM has demonstrated its ability to increase the expression levels of MBNL, both MBNL1 and MBNL2, and their effective amount in the nucleus of human DM1 myoblasts.
Muscleblind-like proteins (MBNL) are key regulators of mRNA metabolism in mammals. MBNL is involved in 80% of the regulatory mechanisms of the multisystemic effects of DM1. In this sense, an increase in MBNL could represent an improvement in at least 80% of the multisystemic effects of the disease.
MBNL1 is the most studied member of the MBNL protein family due to its predominant expression in muscle tissues, as well as in the brain, heart, and liver. It is also an important regulator of the alternative processing of transcripts. Hundreds of alternative exons have their processing altered in DM1, and some of them are directly correlated with DM1 symptoms. In fact, the functional decrease of MBNL1 is the key element in the pathogenesis of DM1. It has been found that the lack of MBNL function in humans causes a defect in the transition from fetal to adult splicing patterns in all MBNL-regulated transcripts.
The combination of caffeine and theobromine in a very specific ratio (determined through a long research process) is incorporated into the MYODM supplement, demonstrating a synergistic effect in the increase of MBNL1 at both the transcription and protein level after administration to human DM1 myoblasts. When administered to DM1 model animals, MYODM increases their survival, improves muscle area, cardiac dysfunction, and locomotor dysfunction, and reduces redox and autophagy levels in these experimental animals. Therefore, MYODM is capable of rescuing in vivo the DM1-related phenotypes and globally improving the quality of life of DM1 model individuals fed with the product.
CAFFEINE AND THEOBROMINE AS INGREDIENTS OF MYODM
The main ingredients of MYODM are the methylxanthines theobromine and caffeine, formulated at the optimal composition and doses obtained during the research and development of the product. Methylxanthines are secondary metabolites from plants derived from purine nucleosides, and are present in nearly 100 different plant species (including Theobroma cacao, Coffea arabica, and Camellia sinensis).
No other food contains the formulated ratio of theobromine and caffeine found in MYODM.
CAFFEINE AS AN INGREDIENT OF MYODM
MYODM contains 20 mg of caffeine per capsule. The daily intake of three evenly spaced capsules results in a maximum intake of 60 mg.
MYODM complies with current legislation regarding caffeine content in dietary supplements, for which a maximum daily amount of 80 mg is accepted.
Taking one capsule of MYODM (with its 20 mg of caffeine) represents an intake of 0.28 mg/kg in an individual weighing 70 kg.
The European Food Safety Authority (EFSA), in its expert reports (“Scientific Opinion on the safety of caffeine,” EFSA Journal 2015;13(5):4102), states that in the general healthy population, single doses of caffeine up to 3 mg/kg for a 70 kg adult (equivalent to 200 mg of caffeine in a single intake) are safe. In general, regular caffeine doses of up to 400 mg/day are considered safe for adults.
Therefore, EFSA indicates that a dose ten times higher than the amount of caffeine in one MYODM capsule is considered safe.
